Wu Lin, Huang Weiyi, Liu Xiaoxiao, Yang Baochun
Department of Pharmacy, The Affiliated Wuxi NO. 2 People's Hospital of Nanjing Medical University, Wuxi, China.
Department of Neurosurgery, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China.
Vascular. 2023 Dec;31(6):1201-1208. doi: 10.1177/17085381221112551. Epub 2022 Jul 20.
To investigate the clinical effects of acipimox in patients with vulnerable carotid atherosclerosis.
80 patients with vulnerable carotid atherosclerosis who were admitted to the Department of Cardiology in Wuxi Second People's Hospital between February 2020 and October 2021 were enrolled in this study. All of these patients were randomly divided into an observation group ( = 40), who were given acipimox and conventional treatment, and a control group ( = 40), who were given conventional treatment. The levels of blood lipids and adiponectin (APN), the carotid intima-media thickness (IMT), the area, thickness and number of CAS, peak systolic velocities (PSV) and end-diastolic blood velocity (EDV) of common carotid artery (CCA), and the level of inflammatory markers were measured and compared between the two groups pretherapy and posttreatment. Then, the adverse events were collected and compared between the two groups posttreatment.
The demographics and basic clinical characteristics were not significantly different between the two groups. At posttreatment, the levels of TC, LDL-C, ANP, IL-6, TNF-α and hs-CRP in the observation group were significantly lower than those in the control group at posttreatment. Moreover, the IMT and the area and thickness of CAS in the observation group were significantly lower than those in the control group. After treatment, PSV was lower and EDV was higher in two groups than before treatment; after treatment, compared with control group, PSV in observation group was lower, while EDV was higher. Most importantly, the rate of adverse events was similar in the two groups.
Acipimox reduced the blood lipid levels in patients with vulnerable carotid atherosclerosis. It also stabilized vulnerable plaques and reduced CAS.
探讨阿昔莫司对易损性颈动脉粥样硬化患者的临床疗效。
选取2020年2月至2021年10月在无锡市第二人民医院心内科住院的80例易损性颈动脉粥样硬化患者纳入本研究。所有患者随机分为观察组（n = 40），给予阿昔莫司及常规治疗；对照组（n = 40），给予常规治疗。分别于治疗前及治疗后测量并比较两组患者的血脂、脂联素（APN）水平、颈动脉内膜中层厚度（IMT）、颈动脉粥样硬化斑块（CAS）面积、厚度及数量、颈总动脉（CCA）的收缩期峰值流速（PSV）和舒张末期血流速度（EDV），以及炎症标志物水平。然后，收集两组治疗后的不良事件并进行比较。
两组患者的人口统计学和基本临床特征无显著差异。治疗后，观察组患者的总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、脂联素（ANP）、白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）和超敏C反应蛋白（hs-CRP）水平均显著低于对照组。此外，观察组的IMT以及CAS的面积和厚度均显著低于对照组。治疗后，两组的PSV均降低，EDV均升高；治疗后，与对照组相比，观察组的PSV更低，而EDV更高。最重要的是，两组的不良事件发生率相似。
阿昔莫司可降低易损性颈动脉粥样硬化患者的血脂水平。它还能稳定易损斑块并减少颈动脉粥样硬化斑块。
